Summary of Study ST001712
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001096. The data can be accessed directly via it's Project DOI: 10.21228/M81M6P This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
Study ID | ST001712 |
Study Title | Metabolomics analysis of plasma from a mouse model of astrocytoma subjected to radiotherapy |
Study Summary | Mice were randomized in two groups (n=9 mice/group), one group was subjected to radiotherapy (Monday and Friday for 2 consecutive weeks at 3Gy/session) and the other cohort was the control. Sample were taken approximately each 10 days from the tail vein. |
Institute | National Cancer Institute |
Last Name | Larion |
First Name | Mioara |
Address | 37 Convent Dr, Building 37 Room 1136 |
mioara.larion@nih.gov | |
Phone | 2407606825 |
Submit Date | 2021-02-26 |
Analysis Type Detail | LC-MS |
Release Date | 2021-03-09 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Treatment:
Treatment ID: | TR001802 |
Treatment Summary: | Radiation was performed on mice intracranially injected with the NCH1681 cell line. Mice were irradiated with a total of 12Gy; specifically, animals were treated on Monday and Friday for 2 consecutive weeks at 3Gy/session. Radiation was performed in a Pantek machine an orthovoltage radiotherapy unit. The mice were anesthetized with a cocktail of ketamine/rompun/saline mixture, i.e. ketamine (100mg/ml), rompun (20mg/ml) and diluted with saline to give the mice a 100mg/kg dose of ketamine and 10mg/kg rompun. The mice were injected with the cocktail at a dose of 0.01 µL per gram of half of the mouse’s body weight. Animals were then placed in a custom-made jig. During radiation, lead shielding covered the eyes, ears, the oral cavity, and the spinal cord. After radiation, the mice were given atipamezole, a reversal agent, to aid in the recovery. |